Metabolic syndrome in the prediction of cardiovascular events: The potential additive role of hsCRP and adiponectin

European Journal of Preventive Cardiology

Volumn 21, Issue 10, 2014, Pages 1242-1248

  Santaniemi, Merja ^a   Ukkola, Olavi ^a   Malo, Elina ^a   Bloigu, Risto ^b   Kesäniemi, Y Antero ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF OULU   (Finland)

Author keywords

Cardiovascular diseases; inflammation; obesity; risk factors

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; HIGH SENSITIVITY C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ADIPOQ PROTEIN, HUMAN; BIOLOGICAL MARKER;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREDICTION; PROSPECTIVE STUDY; SEX DIFFERENCE; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; BLOOD; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; CORONARY DISEASE; FINLAND; HYPERTENSION; KAPLAN MEIER METHOD; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK ASSESSMENT; RISK FACTOR; STROKE; TIME;

ADIPONECTIN; ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; FINLAND; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; KAPLAN-MEIER ESTIMATE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; STROKE; TIME FACTORS;

EID: 84907541194     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487313494028     Document Type: Article

References (27)

1. Grundy SM. Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol. 2012 ; 59 (7). 635-643
2. Matsuzawa Y, Funahashi T, Nakamura T. The concept of metabolic syndrome: Contribution of visceral fat accumulation and its molecular mechanism. J Atheroscler Thromb. 2011 ; 18 (8). 629-639
3. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009 ; 120 (16). 1640-1645
4. Santaniemi M, Kesäniemi YA, Ukkola O. Low plasma adiponectin concentration is an indicator of the metabolic syndrome. Eur J Endocrinol. 2006 ; 155 (5). 745-750
5. Genest J. C-reactive protein: Risk factor, biomarker and/or therapeutic target?. Can J Cardiol. 2010 ; 26: 41A - 44A
6. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?. Circulation. 2004 ; 109 (23). 2818-2825
7. Rantala AO, Kauma H, Lilja M, et al. Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects. J Intern Med. 1999 ; 245 (2). 163-174
8. Pajunen P, Jousilahti P, Borodulin K, et al. Body fat measured by a near-infrared interactance device as a predictor of cardiovascular events: The FINRISK'92 cohort. Obesity. 2011 ; 19 (4). 848-852
9. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010 ; 56 (14). 1113-1132
10. Oda E. The metabolic syndrome as a concept of adipose tissue disease. Hypertens Res. 2008 ; 31 (7). 1283-1291
11. Ford ES. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: Findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis. 2003 ; 168 (2). 351-8
12. Ford ES, Ajani UA, Mokdad AH. The metabolic syndrome and concentrations of C-reactive protein among U.S. youth. Diabetes Care. 2005 ; 28 (4). 878-81
13. Laugsand LE, Asvold BO, Vatten LJ, et al. Metabolic factors and high-sensitivity C-reactive protein: The HUNT study. Eur J Prev Cardiol. 2012 ; 19 (5). 1101-10
14. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003 ; 107 (3). 391-397
15. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial. Lancet. 2009 ; 373 (9670). 1175-1182
16. Emberson J, Bennett D, Link E, et al. C-reactive protein concentration and the vascular benefits of statin therapy: An analysis of 20,536 patients in the Heart Protection Study. Lancet. 2011 ; 377 (9764). 469-476
17. Pilz S, Maerz W, Weihrauch G, et al. Adiponectin serum concentrations in men with coronary artery disease: The LUdwigshafen RIsk and Cardiovascular Health (LURIC) study. Clin Chim Acta. 2006 ; 364 (1-2). 251-255
18. Wannamethee SG, Whincup PH, Lennon L, Sattar N. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med. 2007 ; 167 (14). 1510-1517
19. Wannamethee SG, Whincup PH, Rumley A, Lowe GD. Inter-relationships of interleukin-6, cardiovascular risk factors and the metabolic syndrome among older men. J Thromb Haemost. 2007 ; 5 (8). 1637-1643
20. Laughlin GA, Barrett-Connor E, May S, Langenberg C. Association of adiponectin with coronary heart disease and mortality: The Rancho Bernardo study. Am J Epidemiol. 2007 ; 165 (2). 164-174
21. Pischon T, Hu FB, Girman CJ, et al. Plasma total and high molecular weight adiponectin levels and risk of coronary heart disease in women. Atherosclerosis. 2011 ; 219 (1). 322-329
22. Sattar N, Wannamethee G, Sarwar N, et al. Adiponectin and coronary heart disease: A prospective study and meta-analysis. Circulation. 2006 ; 114 (7). 623-629
23. Ogorodnikova AD, Wassertheil-Smoller S, Mancuso P, et al. High-molecular-weight adiponectin and incident ischemic stroke in postmenopausal women: A Women's Health Initiative Study. Stroke. 2010 ; 41 (7). 1376-1381
24. Lawlor DA, Davey Smith G, Ebrahim S, et al. Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab. 2005 ; 90 (10). 5677-5683
25. Kizer JR, Barzilay JI, Kuller LH, Gottdiener JS. Adiponectin and risk of coronary heart disease in older men and women. J Clin Endocrinol Metab. 2008 ; 93 (9). 3357-3364
26. Sattar N, Watt P, Cherry L, et al. High molecular weight adiponectin is not associated with incident coronary heart disease in older women: A nested prospective case-control study. J Clin Endocrinol Metab. 2008 ; 93 (5). 1846-1849
27. Wannamethee SG, Welsh P, Whincup PH, et al. High adiponectin and increased risk of cardiovascular disease and mortality in asymptomatic older men: Does NT-proBNP help to explain this association?. Eur J Cardiovasc Prev Rehabil. 2011 ; 18 (1). 65-71